AI assistant
Neovacs — Earnings Release 2014
May 13, 2015
1546_iss_2015-05-13_ac13bc13-5675-47c9-978c-3b3ce5b6fb98.pdf
Earnings Release
Open in viewerOpens in your device viewer
PRESS RELEASE PRESS RELEASE PRESS RELEASE
NEOVACS GRANTED 1.8 MILLION EURO IN RESEARCH TAX CREDIT
Paris and Boston, May 13, 2015 – NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has received €1.8 million in research tax credit for R&D expenses incurred in 2014.
The funds received through the tax credit will be used to fund the clinical and pre-clinical development of Neovacs' therapeutic vaccines portfolio.
"We are actively pursuing the clinical development of IFNα-Kinoid in lupus and dermatomyositis, while carefully controlling our expenditures. The phase IIb clinical trial of IFNα-Kinoid in lupus will be initiated in the coming months in Europe, Asia and Latin America; it will be followed by a phase I/II trial in the U.S. in early 2016" commented Miguel Sieler, Chief Executive Officer of Neovacs.
The anticipated paiement of the research tax credit for 2014 was obtained through a pre-financing mechanism put in place with NEFTYS Conseil.
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, please visit www.neovacs.fr
Contacts
+33 (0)1 53 10 93 00 +33 (0)1 44 71 94 94 [email protected] [email protected]
NEOVACS – Investor Relations Investor Relations / Financial Communications – NewCap Nathalie Trépo Valentine Brouchot / Pierre Laurent